Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
CLARITY-PanTumour01
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
- NCT06219941 ↗
- Recruiting
- AstraZeneca
- Focused
We haven't built an HCP commentary report on CLARITY-PanTumour01 (sonesitatug vedotin (AZD0901) in claudin 18.2-expressing advanced solid tumors) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on CLARITY-PanTumour01 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| YouTube | 2 | |
| Podcasts | 2 | |
| X threads | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase II, Open-label, Multi-centre Study to Evaluate Safety, Tolerability, Efficacy, PK, and Immunogenicity of AZD0901 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Tumours Expressing Claudin 18.2 (CLARITY-PanTumour01)
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- Gastric Cancer; Gastroesophageal Junction Cancer; Biliary Tract Cancer; Pancreatic Ductal Adenocarcinoma
- Interventions
- AZD0901; 5-Fluorouracil; Leucovorin; l-leucovorin; Irinotecan; Nanoliposomal Irinotecan; Gemcitabine
- Arms
- Sub Study 1 - AZD0901 MONOTHERAPY · Experimental
- Sub Study 2 - AZD0901 IN COMBINATION WITH ANTI-CANCER AGENTS IN PANCREATIC DUCTAL ADENOCARCINOMA · Experimental
- Sub Study 3: AZD0901 MONOTHERAPY IN BILIARY TRACT CANCER · Experimental
- Enrollment
- 226 (estimated)
- Primary outcomes
- Incidence of adverse events (AEs), serious AEs (SAEs). Changes from baseline in clinical laboratory parameters, vital signs, ECGs and physical examination. Rate of AEs leading to discontinuation of AZD0901, Occurrence of DLTs.
- Objective Response Rate (ORR).
- Sponsor
- AstraZeneca
- Start
- Dec 13, 2023
- Primary completion
- Nov 17, 2026 (estimated)
- Results posted
- No
- Registry record
- NCT06219941 · updated Sep 30, 2026